RxDoctor Payments Data

Graham Byrum, MD

Interventional Cardiology · Winston Salem, NCNPI 1598021560

Payments from drug & device makers

$3,833in general payments, 2019–2025

Across 57 payments — averaging $67.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Abiomed$833
  • Abbott$456
  • Edwards Lifesciences$272
  • AstraZeneca$249
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$87
  • plus $265 from 7 others

What the payments were for

  • Travel & lodging$1,12129%
  • Food & beverage$2,44864%
  • Education$2657%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,833 in reported general payments places this provider in the 25th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$76,130
Medicare patients
472
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$207,156
XareltoRivaroxaban47$48,706
BrilintaTicagrelor24$24,714
Repatha SureclickEvolocumab25$22,611
Metoprolol Succinate145$1,661
Isosorbide Mononitrate ErIsosorbide Mononitrate153$1,302
Atorvastatin Calcium125$943
Losartan Potassium93$814
Amlodipine Besylate132$773
Flecainide Acetate19$674
Lisinopril108$663
Rosuvastatin Calcium64$649
Carvedilol95$627
Furosemide139$620
Amiodarone Hcl25$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$207,156157 claims
Johnson & JohnsonXarelto$24$48,70647 claims
AstraZenecaBrilinta$249$24,71424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →